Total : %
04.22.18 12:20:34PM
Past Data
| Ticker | Date | Current phase | Disease Area | Market cap | Trial outcome | Ticker Prob 1 | Ticker Prob 2 | Phase Prob | Disease Prob | MC Prob | Quarter |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ITEK | 08/19/2017 | 3 | Opthalmology | $240M | fail | 43.80% | 40.9 | Quarter | |||
| AGRX | 08/19/2017 | 3 | other | $143.73m | fail | 48% | 47.5 | Quarter | |||
| OTIC | 08/19/2017 | 3 | Infectious disease | $489.15M | success | 54.60% | 51.85 | Quarter | |||
| TENX | 08/19/2017 | 3 | Other | $65.24M | fail | 42% | 47.5 | Quarter | |||
| ANTH | 08/19/2017 | 3 | Autoimmune | $89.3m | Fail | 46.20% | 34.1 | Quarter | |||
| OPHT | 08/19/2017 | 3 | Ophthalmology | $1.3B | fail | 51.60% | 52.6 | Quarter | |||
| NOVN | 08/19/2017 | 3 | Skin infections | $305m | fail 1/27 | 55% | 51.75 | Quarter | |||
| CATB | 08/19/2017 | 2 | other | $75.1M | fail | 33.30% | 31.9 | 9.9 | 22 | Quarter | |
| TRVN | 08/19/2017 | 3 | other | $372M | success | 52.8 | 50.75 | Quarter | |||
| AVIR | 08/19/2017 | 2 | infections disease | $48.69M | fail | 35.7 | 33.55 | 9.9 | 23.65 | 0 | Quarter |
| AXON | 08/19/2017 | 2 | Dementia | $1.22B | 16.8 | 11.7 | Quarter | ||||
| NDRM | 08/19/2017 | 2 | Neurology | $600.73m | Success | 28.8 | 29.4 | Quarter | |||
| CELG | 08/19/2017 | 3 | Multiples Scerosis (Other) | 94B | Success | 59.2 | 9 | 38.5 | 11.7 | Quarter | |
| CDTX | 08/19/2017 | 2 | Infection | $195.08M | fail | 35.4 | 33.55 | Quarter | |||
| CYCC | 08/19/2017 | 3 | Other | $22M | fail | 51 | 47.5 | Quarter | |||
| BCRX | 08/19/2017 | 2 | -- | $406.21M | Quarter | ||||||
| LJPC | 08/19/2017 | 3 | Cardiovascular | 332.59M | Success* | 41.95 | Quarter | ||||
| ACOR | 08/19/2017 | 3 | Neurology/Parkinson's dz | $943M | Success | 52.05 | Quarter | ||||
| PTCT | 08/19/2017 | 3 | Other | $448.54M | fail | 50.2 | Quarter | ||||
| AUPH | 08/19/2017 | 2 | Autoimmune | $196.65m | Success | 27.5 | Quarter | ||||
| KPTI | 08/19/2017 | 2 | Other | $570.81M | fail | 31.9 | Quarter | ||||
| TGTX | 08/19/2017 | 3 | Other | $292.81M | Success* | 47.5 | Quarter | ||||
| IONS | 08/19/2017 | 3 | Other | $6.10B | Success | 59.2 | Quarter | ||||
| NKTR | 08/19/2017 | 3 | Other (Opiod) | $2.37B | Success | 59.2 | Quarter | ||||
| CRBP | 08/19/2017 | 2 | Cystic Fibrosis (Other) | $462.67M | 34.6 | Quarter | |||||
| GNMX | 2 | Other | $219.99M | fail | 31.9 | Quarter | |||||
| LLY | 3 | Other (Breast Cancer) | $88.38B | Success | 59.2 | Quarter | |||||
| RARE | 2 | Other (Seizure) | $3.27b | FAIL | 43.6 | Quarter | |||||
| XENE | 2 | Other (facial acne) | 176.67M | fail | 31.9 | Quarter | |||||
| FOMX | 3 | All indications | $338.23M | FAIL | 44.5 | Quarter | |||||
| VRTX | 3 | Other (Cystic Fibrosis) | $22.28B | Success | 55.7 | Quarter | |||||
| PRTK | 3 | Infections disease | $495.86M | Success | 51.85 | Quarter | |||||
| NVCR | 3 | Oncology | $713.52M | Success | 33.7 | Quarter | |||||
| OMED | 2 | Oncology | $327.61M | Fail | 26.35 | Quarter | |||||
| RARE | 3 | Other | $2.50B | Success | 59.2 | Quarter | |||||
| NTRP | 2 | Alzheimer's | $147.43M | Fail | 9.9 | Quarter | |||||
| AEZS | 3 | Other | $49.93M | Fail | 48.4 | Quarter | |||||
| ITEK | 2 | Opthalmology | 46.55M | Fail | 33.75 | Quarter | |||||
| ZYNE | 2 | Others | $200M | 31.9 | Quarter |
